AFM 32
Alternative Names: AFM-32; AFVT-2101Latest Information Update: 15 Dec 2025
At a glance
- Originator Affimed Therapeutics
- Developer Affivant Sciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants; Monocyte stimulants; Natural killer cell stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Dec 2025 AFM 32 is still in preclinical trial for Solid tumour in USA (Affimed Therapeutics pipeline, December 2025)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 23 May 2023 Affivant plans a phase I trial for Solid tumours in 2023